Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Long-term outcomes, survival predictors and up-front treatment patterns in 568 elderly diffuse large b-cell lymphoma patients from LATAM: Is R-CHOP still the first choice for treating patients older than 60 years?

View Full Paper
Ask AI
Bookmark
Share

Authors

RVR. De VitaNational Agency for New Technologies, Energy and Sustainable Economic DevelopmentISIberê Cauduro SoaresInstituto do Câncer do Estado de São Paulo

Discussion

Loading...

Member takes

Overview

Observational study shows full-dose R-CHOP improves survival in elderly diffuse large B-cell lymphoma, suggesting it remains the preferred therapy.

Key Points

  • To assess long-term outcomes and survival predictors in elderly patients with diffuse large B-cell lymphoma treated with R-CHOP and similar regimens.
  • Retrospective, observational study
  • Involved 568 patients aged ≥ 60 years
  • Analyzed overall response rate, overall survival, and event-free survival
  • Used Cox regression to identify prognostic factors
  • Full-dose R-CHOP showed 61.7% 5-year overall survival
  • R-miniCHOP and Elderly-R-miniCHOP had significantly lower 5-year survival rates
  • Advanced age and frailty were linked to decreased survival
  • Neutropenia rates were higher with full-dose R-CHOP but did not lead to increased treatment discontinuation.

Cite This Study

Vita et al. (2025) studied this question.

synapsesocial.com/papers/69362f7f4fa91c937236e58ehttps://doi.org/10.1182/blood-2025-5437
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Predictors of Survival, Treatment Modalities, and Clinical Outcomes of Diffuse Large B-Cell Lymphoma in Patients Older Than 70 Years Still an Unmet Medical Need in 2024 Based on Real-World Evidence2024 · 11 citations
  2. 2R-mini-CHOP preserves efficacy and limits toxicity for patients ≥ 80 years old with DLBCL2025
  3. 3Determination of the appropriate chemotherapy for patients aged 80 years or older with diffuse large B cell lymphoma2024
  4. 4Tolerability and long-term survival of fragile or older patients with diffuse large B cell lymphoma (DLBCL) not otherwise specified by R-CDOP2025
  5. 5Comparative effectiveness of R-minichop versus R-CHOP in older patients with diffuse large B-cell lymphoma: A propensity score-matched analysis from a real-world grupo de estudio latinoamericano de linfoproliferativos (GELL) cohort2025 · 1 citations